scholarly journals “Tineariasis” (or plaque-psoriasis induced by Terbinafine)

2021 ◽  
Vol 2 (6) ◽  
Author(s):  
Ramirez-Bellver JL ◽  
◽  
Segurado-Miravalles G ◽  
Bagazgoitia L ◽  
Moreno C ◽  
...  
Keyword(s):  
Side Effects ◽  
Skin Biopsy ◽  
Young Patient ◽  
Plaque Psoriasis ◽  
Epidermal Hyperplasia ◽  
Suspected Drug ◽  
Cutaneous Side Effects ◽  
Corneal Layer ◽  
Anti Fungal ◽  
Oral Terbinafine

Terbinafine is an anti fungal drug used worldwide to treat dermatophytosis. Although generally is well tolerated, several cutaneous side effects have been described. One of them is the induction or exacerbation of psoriasis, especially the pustular type. We describe a case of plaque-psoriasis induced by terbinafine in a young patient. Skin biopsy was performed to confirm the diagnosis and the suspected drug was discontinued. Biopsy showed regular epidermal hyperplasia with parakeratoses and neutrophils in the corneal layer. No fungal elements were observed. Improvement was observed after discontinuation of terbinafine. We present a new case of the induction of plaque-psoriasis after the use of oral terbinafine and conclude that this drug should be used with caution in predisposed patients. Keywords: psoriasis; pustular posriasis; plaque-psoriasis; terbinafine

Cutaneous Side Effects in 19 Lung Cancer Patients Treated with Gefitinib (Iressa)

2004 ◽  
Vol 66 (6) ◽  
pp. 602-607 ◽  
Author(s):  
Miho UCHIHIRA ◽  
Takahiro EJIMA ◽  
Takao UCHIHIRA ◽  
Jun ARAKI ◽  
Toshiaki KAMEI
Keyword(s):  
Lung Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Cutaneous Side Effects ◽  
Lung Cancer Patients

scholarly journals Dabigatran Associated Leukocytoclastic Vasculitis

2015 ◽  
Vol 2015 ◽  
pp. 1-2 ◽  
Author(s):  
Evangelos Potolidis ◽  
Charalampos Mandros ◽  
Kalliopi Kotsa ◽  
Evdoxia Mitsiou ◽  
Dimitris Potolidis ◽  
...  
Keyword(s):  
Side Effects ◽  
Skin Biopsy ◽  
Skin Reaction ◽  
Leukocytoclastic Vasculitis ◽  
Skin Reactions ◽  
Usual Therapy

Common side effects of dabigatran are bleeding, bruising, nausea, diarrhea, and abdomen discomfort. Skin reactions were not often noted (<0.1%). We report a case of 70-year-old male who developed dabigatran related skin reaction resistant to usual therapy. Skin biopsy revealed leukocytoclastic vasculitis.

scholarly journals Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Bilgen Gençler ◽  
Müzeyyen Gönül
Keyword(s):  
Side Effects ◽  
Metastatic Melanoma ◽  
Mapk Pathway ◽  
Case Reports ◽  
Mitogen Activated Protein Kinase ◽  
Braf V600e ◽  
Braf Inhibitors ◽  
Braf Mutations ◽  
Cutaneous Side Effects ◽  
Downstream Signaling

The incidence of melanoma has recently been increasing. BRAF mutations have been found in 40–60% of melanomas. The increased activity of BRAF V600E leads to the activation of downstream signaling through the mitogen-activated protein kinase (MAPK) pathway, which plays a key role as a regulator of cell growth, differentiation, and survival. The use of BRAF inhibitors in metastatic melanoma with BRAF mutation ensures clinical improvement of the disease. Vemurafenib and dabrafenib are two selective BRAF inhibitors approved by the Food and Drug Administration (FDA). Both drugs are well tolerated and successfully used in clinical practice. However, some adverse reactions have been reported in patients in the course of treatment. Cutaneous side effects are the most common adverse events among them with a broad spectrum. Both the case reports and several original clinical trials reported cutaneous reactions during the treatment with BRAF inhibitors. In this review, the common cutaneous side effects of BRAF inhibitors in the treatment of metastatic melanoma with BRAF V600E mutation were reviewed.

scholarly journals Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis

PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0255716
Author(s):  
Náthali Felícia Mineiro dos Santos Garrett ◽  
Ana Cristina Carvalho da Costa ◽  
Elaine Barros Ferreira ◽  
Giovanni Damiani ◽  
Paula Elaine Diniz dos Reis ◽  
...  
Keyword(s):  
Systematic Review ◽  
Side Effects ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Cutaneous Toxicity ◽  
Cutaneous Side Effects ◽  
Final Sample

Background Checkpoint inhibitors have revolutionized advanced melanoma care; however, their cutaneous side effects have not been definitively elucidated. Objective To identify the prevalence of cutaneous toxicity in patients with melanoma treated with immune checkpoint inhibitors as monotherapy and/or in combination with chemotherapy and/or radiotherapy. Materials and methods We performed a systematic review and meta-analysis, which encompassed both clinical trials and observational studies describing the dermatological toxicities in patients treated with immune checkpoint inhibitors. The protocol was registered in the International Prospective Register of Systematic Review under the number CRD42018091915. The searches were performed using the CINAHL, Cochrane CENTRAL, LILACS, LIVIVO, PubMed, Scopus, and Web of Science databases. The methodological quality of the studies was evaluated with the JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data Results A total of 9,802 articles were identified in the databases. The final sample comprised 39 studies. The evaluated drugs were ipilimumab, tremelimumab, pembrolizumab, and nivolumab. The results suggest that the most prevalent side effect was grade 1 and 2 pruritus (24%), followed by grade 1 and 2 rash (21%) and grade 1 and 2 vitiligo (10%). Conclusion The most prevalent side effects in patients treated with checkpoint inhibitors are pruritus, rash, and vitiligo, and they are rated mostly as grades 1 and 2 adverse events. Remarkably, vitiligo is most commonly found in patients treated with PD-1 inhibitors.

scholarly journals Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study

2012 ◽  
Vol 67 (6) ◽  
pp. 1265-1272 ◽  
Author(s):  
Emily Y. Chu ◽  
Karolyn A. Wanat ◽  
Christopher J. Miller ◽  
Ravi K. Amaravadi ◽  
Leslie A. Fecher ◽  
...  
Keyword(s):  
Side Effects ◽  
Braf Inhibitor ◽  
Inhibitor Therapy ◽  
Cutaneous Side Effects ◽  
Clinicopathologic Study

Ocular and Cutaneous Side Effects After Prolonged Chlorpromazine Treatment

1967 ◽  
Vol 123 (7) ◽  
pp. 872-874 ◽  
Author(s):  
GEORGE M. GOMBOS ◽  
PAUL E. YARDEN
Keyword(s):  
Side Effects ◽  
Cutaneous Side Effects
Sign in / Sign up

Export Citation Format

Share Document